Abstract

Despite the advances in neonatal intensive care, bronchopulmonary dysplasia (BPD) still remains a major cause of mortality and morbidity in many preterm infants. A definitive treatment still does not exist, and BPD has serious consequences, including poor cardiopulmonary function and development. Hence, to address this need, a randomized clinical trial (NCT03041740) is currently underway to assess the safety and feasibility of partial liquid ventilation (PLV) in preterm infants with severe BPD.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call